S&P 500   5,254.35
DOW   39,807.40
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
S&P 500   5,254.35
DOW   39,807.40
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
S&P 500   5,254.35
DOW   39,807.40
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
S&P 500   5,254.35
DOW   39,807.40
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
NASDAQ:TOI

Oncology Institute (TOI) Stock Price, News & Analysis

$1.58
-0.26 (-14.13%)
(As of 03/28/2024 ET)
Today's Range
$1.52
$1.78
50-Day Range
$1.36
$2.17
52-Week Range
$0.33
$2.66
Volume
289,467 shs
Average Volume
157,358 shs
Market Capitalization
$116.52 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.25

Oncology Institute MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
42.4% Upside
$2.25 Price Target
Short Interest
Healthy
0.76% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.48mentions of Oncology Institute in the last 14 days
Based on 10 Articles This Week
Insider Trading
Selling Shares
$137,838 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.39) to ($0.19) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.66 out of 5 stars

Medical Sector

483rd out of 939 stocks

Offices & Clinics Of Medical Doctors Industry

3rd out of 7 stocks

TOI stock logo

About Oncology Institute Stock (NASDAQ:TOI)

The Oncology Institute, Inc., an oncology company, provides various medical oncology services in the United States. The company operates in three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial services, radiation, outpatient blood product transfusions, and patient support services. The company also offers and manages clinical trial services, such as managing clinical trials, palliative care programs, and stem cell transplants services. It serves adult and senior cancer patients. The Oncology Institute, Inc. was founded in 2007 and is headquartered in Cerritos, California.

TOI Stock Price History

TOI Stock News Headlines

Q4 2023 Oncology Institute Inc Earnings Call
Recap: Oncology Institute Q4 Earnings
Central Banks Preparing for US Dollar Collapse?
China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.
Central Banks Preparing for US Dollar Collapse?
China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.
PCOM, The Wistar Institute Announce Cancer Biology Graduate Program
See More Headlines
Receive TOI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oncology Institute and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
3/29/2024
Next Earnings (Estimated)
5/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Medical Care Facilities
Sub-Industry
N/A
Current Symbol
NASDAQ:TOI
Fax
N/A
Employees
750
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$2.25
High Stock Price Target
$2.50
Low Stock Price Target
$2.00
Potential Upside/Downside
+42.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$150,000.00
Pretax Margin
-24.34%

Debt

Sales & Book Value

Annual Sales
$252.48 million
Cash Flow
$0.02 per share
Book Value
$1.68 per share

Miscellaneous

Free Float
64,088,000
Market Cap
$116.53 million
Optionable
Not Optionable
Beta
0.71
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Mr. Richard Alan Barasch (Age 70)
    Executive Chairman of the Board
  • Mr. Mihir Arunkumar Shah CPA (Age 46)
    Chief Financial Officer & Principal Accounting Officer
    Comp: $393.65k
  • Ms. Hilda Agajanian M.B.A.
    Founder & Chief Growth Officer
  • Dr. Richy Agajanian M.D.
    Founder & Chief Clinical Officer
  • Mr. Rakesh Singh M.B.A.
    Director of Technology
  • Mr. Mark Hueppelsheuser Esq.
    General Counsel
  • Mr. Khurrum Shah J.D.
    M.B.A., Senior Vice President of Compliance
  • Ms. Julie Korinke
    Director of Marketing & Communications
  • Ms. Laura Szitar
    Chief People Officer
  • Dr. Yale D. Podnos F.A.C.S. (Age 52)
    M.D., M.P.H., Chief Medical Officer & President of Practice
    Comp: $345.02k

TOI Stock Analysis - Frequently Asked Questions

Should I buy or sell Oncology Institute stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Oncology Institute in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" TOI shares.
View TOI analyst ratings
or view top-rated stocks.

What is Oncology Institute's stock price target for 2024?

1 brokers have issued 1-year target prices for Oncology Institute's stock. Their TOI share price targets range from $2.00 to $2.50. On average, they expect the company's share price to reach $2.25 in the next twelve months. This suggests a possible upside of 42.4% from the stock's current price.
View analysts price targets for TOI
or view top-rated stocks among Wall Street analysts.

How have TOI shares performed in 2024?

Oncology Institute's stock was trading at $2.04 on January 1st, 2024. Since then, TOI stock has decreased by 22.5% and is now trading at $1.58.
View the best growth stocks for 2024 here
.

When is Oncology Institute's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our TOI earnings forecast
.

What guidance has Oncology Institute issued on next quarter's earnings?

Oncology Institute updated its FY 2024 earnings guidance on Wednesday, March, 27th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $400.0 million-$415.0 million, compared to the consensus revenue estimate of $378.8 million.

Who are Oncology Institute's major shareholders?

Oncology Institute's stock is owned by many different retail and institutional investors. Top institutional investors include Josh Arnold Investment Consultant LLC (2.52%), Vanguard Group Inc. (2.41%), Vanguard Group Inc. (2.41%), Balyasny Asset Management L.P. (1.70%), Kent Lake Capital LLC (1.47%) and Cincinnati Insurance Co. (0.95%). Insiders that own company stock include Brad Hively, Havencrest Healthcare Partners, Matthew P Miller, Mohit Kaushal, Richard A Barasch and Richy Agajanian.
View institutional ownership trends
.

How do I buy shares of Oncology Institute?

Shares of TOI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:TOI) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners